As part of their economic development strategies, countries outside of the U.S. continue to grow their life sciences and biopharmaceutical presence, gaining on the U.S. leadership in biopharmaceutical R&D, according to a new report prepared by Teconomy Partners LLC for the Pharmaceutical Research and Manufacturers of America (PhRMA).
The rheumatoid arthritis (RA) market has come a long way since Enbrel (etanercept, Amgen Inc.) was first approved to treat the disease in 1998. Nearly two decades later, there are now a handful of additional TNF-alpha inhibitors, including some long-acting varieties, and multiple other drugs working through different mechanisms of action that have been approved by the FDA to treat RA. In addition to the multitude of biologics, there's even an oral disease-modifying antirheumatic drug (DMARD), Xeljanz (tofacitinib, Pfizer Inc.) that works by inhibiting Janus kinase (JAK).
As companies develop artificial intelligence (AI) platforms using big data to aid in drug development, they have to balance providing the service for external development of customers' and partners' drugs with internal development of their own drugs.
Collaboration has become increasingly important in drug development. There's a consortium for seemingly every disease as well as those designed to increase clinical trial efficiency and large-scale screening of compounds.
On Thursday, cystic fibrosis powerhouse Vertex Pharmaceuticals Inc. reported solid first-quarter sales of its drugs, Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor), designed to modulate CFTR, which is mutated in cystic fibrosis patients, but it was the pipeline of next-generation drugs that received the most attention.
The European Patent Office (EPO) recently issued a broad patent for the use of CRISPR/Cas9 single-guide gene editing system to Emmanuelle Charpentier, regents of the University of California and University of Vienna.
Last week, the European Patent Office (EPO) issued a broad patent for the use of CRISPR/Cas9 single-guide gene editing system to Emmanuelle Charpentier, regents of the University of California and University of Vienna.
Last year wasn't the best for venture capital investments in U.S. private companies, with the total for the year headed in the wrong direction, failing to match 2015 levels. (See BioWorld Today, Jan. 4, 2017.)
To push the envelope – increasing survival and decreasing toxicity – companies are harnessing new technology and mechanisms of action to develop the next generation of oncology drugs.
To push the envelope – increasing survival and decreasing toxicity – companies are harnessing new technology and mechanisms of action to develop the next generation of oncology drugs.
